The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
The FDA approves the first-of-its-kind treatment for anemia caused by CKD for adults who receive dialysis following the results of a randomized clinical trial.
The US Food and Drug Administration has approved the first drug to slow the decline of kidney function in adults with a high risk of rapidly progressing autosomal dominant polycystic kidney disease.
